or Use Alternate Drug. fluvoxamine will increase the level or effect of dronedarone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.duloxetineSerious - Use Alternative (2)fluvoxamine will increase the level or effect of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. fluvoxamine and duloxetine both increase serotonin levels. Avoid or Use Alternate Drug.edoxabanMonitor Closely (1)fluvoxamine will increase the level or effect of edoxaban by anticoagulation. Use Caution/Monitor. SSRIs affect platelet activation; coadministration may increase risk of bleedingefavirenzMonitor Closely (2)fluvoxamine will increase the level or effect of efavirenz by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. efavirenz and fluvoxamine both increase QTc interval. Use Caution/Monitor.elacestrantSerious - Use Alternative (1)fluvoxamine will increase the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eletriptanMonitor Closely (1)fluvoxamine and eletriptan both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustatMonitor Closely (1)eliglustat will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations; consider reducing dosage of concomitant drug and titrate to clincal effectSerious - Use Alternative (1)eliglustat and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.eltrombopagMonitor Closely (1)fluvoxamine will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.eluxadolineMonitor Closely (2)fluvoxamine will increase the level or effect of eluxadoline by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Use caution when coadministering with CYP2C19 inhibitors; not studied fluvoxamine will increase the level or effect of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Use caution when coadministering with strong CYP1A2 inhibitors; Not studiedelvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Caution with CYP2D6 substrates for which elevated plasma concentrations may cause life-threatening eventsencorafenibSerious - Use Alternative (1)encorafenib and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (2)fluvoxamine will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidabole, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.5m2. Resume previous entrectinib dose after discontinuing moderate CYP3A4 inhibitor for 3-5 elimination half-lives. entrectinib and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.epcoritamabMonitor Closely (1)epcoritamab, fluvoxamine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Epcoritamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .epinephrineMonitor Closely (1)fluvoxamine and epinephrine both increase QTc interval. Modify Therapy/Monitor Closely.epinephrine racemicMonitor Closely (1)fluvoxamine and epinephrine racemic both increase QTc interval. Modify Therapy/Monitor Closely.ergotamineMonitor Closely (1)fluvoxamine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.eribulinSerious - Use Alternative (1)eribulin and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.erlotinibMonitor Closely (1)fluvoxamine will increase the level or effect of erlotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin baseMonitor Closely (1)fluvoxamine and erythromycin base both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin ethylsuccinateMonitor Closely (1)fluvoxamine and erythromycin ethylsuccinate both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin lactobionateMonitor Closely (1)fluvoxamine and erythromycin lactobionate both increase QTc interval. Modify Therapy/Monitor Closely.erythromycin stearateMonitor Closely (1)fluvoxamine and erythromycin stearate both increase QTc interval. Modify Therapy/Monitor Closely.escitalopramSerious - Use Alternative (1)fluvoxamine and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug.esomeprazoleSerious - Use Alternative (1)fluvoxamine will increase the level or effect of esomeprazole by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.ethinylestradiolMonitor Closely (1)ethinylestradiol will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.ethotoinMonitor Closely (1)fluvoxamine will increase the level or effect of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.etodolacMonitor Closely (1)fluvoxamine, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.etravirineMonitor Closely (1)fluvoxamine will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.everolimusSerious - Use Alternative (1)fluvoxamine will increase the level or effect of everolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of CYP2D6 substrates as necessarySerious - Use Alternative (1)fluvoxamine will increase the level or effect of fedratinib by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadminitration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib not studiedfelodipineMonitor Closely (1)fluvoxamine will increase the level or effect of felodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fenbufenMonitor Closely (1)fluvoxamine, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.fenfluramineMonitor Closely (2)fenfluramine, fluvoxamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. fluvoxamine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenoprofenMonitor Closely (1)fluvoxamine, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fentanylSerious - Use Alternative (1)fluvoxamine and fentanyl both increase serotonin levels. Avoid or Use Alternate Drug.fentanyl transdermalSerious - Use Alternative (1)fluvoxamine and fentanyl transdermal both increase serotonin levels. Avoid or Use Alternate Drug.fentanyl transmucosalSerious - Use Alternative (1)fluvoxamine and fentanyl transmucosal both increase serotonin levels. Avoid or Use Alternate Drug.fesoterodineMonitor Closely (1)fluvoxamine will increase the level or effect of fesoterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fexinidazoleMonitor Closely (1)fexinidazole will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.fezolinetantContraindicated (1)fluvoxamine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsfinerenoneMonitor Closely (1)fluvoxamine will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or moderate CYP3A4 inhibitors. Adjust finererone dosage as needed.fingolimodMonitor Closely (1)fingolimod and fluvoxamine both increase QTc interval. Use Caution/Monitor.fish oil triglyceridesMonitor Closely (1)fish oil triglycerides will increase the level or effect of fluvoxamine by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulantsflecainideMonitor Closely (1)fluvoxamine and flecainide both increase QTc interval. Use Caution/Monitor.flibanserinMonitor Closely (1)fluvoxamine will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. May increase risk of hypotension, syncope, and CNS depressionfluconazoleMonitor Closely (1)fluvoxamine and fluconazole both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetineSerious - Use Alternative (1)fluvoxamine and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (1)fluvoxamine and fluphenazine both increase QTc interval. Use Caution/Monitor.flurbiprofenMonitor Closely (1)fluvoxamine, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor.fluvastatinMonitor Closely (1)fluvoxamine will increase the level or effect of fluvastatin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.fondaparinuxMonitor Closely (1)fluvoxamine will increase the level or effect of fondaparinux by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, which may increase bleeding risk when coadministered with anticoabulantsformoterolMonitor Closely (1)fluvoxamine and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.fosamprenavirMonitor Closely (1)fluvoxamine will increase the level or effect of fosamprenavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetMonitor Closely (1)fluvoxamine and foscarnet both increase QTc interval. Use Caution/Monitor.fosphenytoinMonitor Closely (1)fluvoxamine will increase the level or effect of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.frovatriptanMonitor Closely (1)fluvoxamine and frovatriptan both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentinMonitor Closely (1)fluvoxamine, gabapentin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coaadministration with CNS depressant may result in fatal respiratory depression. Use lowest dose possible and monnitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)fluvoxamine, gabapentin enacarbil. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coaadministration with CNS depressant may result in fatal respiratory depression. Use lowest dose possible and monnitor for respiratory depression and sedation.ganaxoloneMonitor Closely (1)fluvoxamine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)gemifloxacin and fluvoxamine both increase QTc interval. Use Caution/Monitor.gilteritinibSerious - Use Alternative (2)gilteritinib will increase the level or effect of fluvoxamine by Other (see comment). Avoid or Use Alternate Drug. Coadministrationwith drugs that inhibit 5HT2B or sigma nonspecific receptors. Avoid use of these drugs with gilteritinib unless coadministration is necessary gilteritinib and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.givosiranSerious - Use Alternative (2)givosiran will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling. givosiran will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glofitamabMonitor Closely (1)glofitamab, fluvoxamine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .granisetronMonitor Closely (1)granisetron and fluvoxamine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)fluvoxamine and granisetron both increase serotonin levels. Avoid or Use Alternate Drug.grapefruitMonitor Closely (1)grapefruit will increase the level or effect of fluvoxamine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.green teaMonitor Closely (1)green tea, fluvoxamine. Either increases toxicity of the other by anticoagulation. Use Caution/Monitor.guanfacineMonitor Closely (1)fluvoxamine will increase the level or effect of guanfacine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministered with extended release, reduce guanfacine dosage in half of recommended dose; specific recommendation for immediate release form not availablehaloperidolMonitor Closely (1)fluvoxamine and haloperidol both increase QTc interval. Modify Therapy/Monitor Closely.hydrocodoneMonitor Closely (1)fluvoxamine and hydrocodone both increase serotonin levels. Use Caution/Monitor. If concomitant use warranted, carfully observe patient, particularly during treatment initiation and dose adjustmenthydromorphoneSerious - Use Alternative (1)fluvoxamine and hydromorphone both increase serotonin levels. Avoid or Use Alternate Drug.hydroxyzineMonitor Closely (1)hydroxyzine and fluvoxamine both increase QTc interval. Use Caution/Monitor.ibrutinibMonitor Closely (1)ibrutinib will increase the level or effect of fluvoxamine by anticoagulation. Use Caution/Monitor. Ibrutinib may increase risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleedingibuprofenMonitor Closely (1)fluvoxamine, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets.ibuprofen IVMonitor Closely (1)fluvoxamine, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ibutilideSerious - Use Alternative (1)fluvoxamine and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.ifosfamideMonitor Closely (1)fluvoxamine will decrease the level or effect of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. CYP2B6 inhibitors may decrease metabolism of ifosfamide to its active metabolite, potentially reducing ifosfamide therapeutic effectsiloperidoneMonitor Closely (1)fluvoxamine and iloperidone both increase QTc interval. Use Caution/Monitor.imatinibMonitor Closely (1)imatinib will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipramineMonitor Closely (1)fluvoxamine will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.indapamideSerious - Use Alternative (1)fluvoxamine and indapamide both increase QTc interval. Avoid or Use Alternate Drug.indinavirMonitor Closely (1)fluvoxamine will increase the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.indomethacinMonitor Closely (1)fluvoxamine, indomethacin.